PreveCeutical Medical Inc. announced that PreveCeutical is furthering the progress of its patent family directed to Sol-Gel (International Patent Application No. PCT/AU2021/051383, Sol-Gel Cannabinoid Formulation and Antiviral Use) and is taking the International patent application forward in the US and Canada, with plans to progress in Europe and Australia also. The US patent application (USSN 18/253,573) has been filed with amended claims, together with its Canadian counterpart.

PreveCeutical is prosecuting the patent applications to maximize the scope of protection available in those countries and to ensure that effective and secure patents are obtained as the company continue clinical process.